Are biosimilars the next tool to guarantee cost-containment for pharmaceutical expenditures?

Detalles Bibliográficos
Autores principales: Farfan-Portet, María-Isabel, Gerkens, Sophie, Lepage-Nefkens, Isabelle, Vinck, Irmgard, Hulstaert, Frank
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2013
Materias:
Editorial
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3950601/
https://www.ncbi.nlm.nih.gov/pubmed/24271016
http://dx.doi.org/10.1007/s10198-013-0538-4
_version_ 1782307014818398208
author Farfan-Portet, María-Isabel
Gerkens, Sophie
Lepage-Nefkens, Isabelle
Vinck, Irmgard
Hulstaert, Frank
author_facet Farfan-Portet, María-Isabel
Gerkens, Sophie
Lepage-Nefkens, Isabelle
Vinck, Irmgard
Hulstaert, Frank
author_sort Farfan-Portet, María-Isabel
collection PubMed
description
format Online
Article
Text
id pubmed-3950601
institution National Center for Biotechnology Information
language English
publishDate 2013
publisher Springer Berlin Heidelberg
record_format MEDLINE/PubMed
spelling pubmed-39506012014-03-20 Are biosimilars the next tool to guarantee cost-containment for pharmaceutical expenditures? Farfan-Portet, María-Isabel Gerkens, Sophie Lepage-Nefkens, Isabelle Vinck, Irmgard Hulstaert, Frank Eur J Health Econ Editorial Springer Berlin Heidelberg 2013-11-23 2014 /pmc/articles/PMC3950601/ /pubmed/24271016 http://dx.doi.org/10.1007/s10198-013-0538-4 Text en © The Author(s) 2013 https://creativecommons.org/licenses/by/2.0/ Open AccessThis article is distributed under the terms of the Creative Commons Attribution License which permits any use, distribution, and reproduction in any medium, provided the original author(s) and the source are credited.
spellingShingle Editorial
Farfan-Portet, María-Isabel
Gerkens, Sophie
Lepage-Nefkens, Isabelle
Vinck, Irmgard
Hulstaert, Frank
Are biosimilars the next tool to guarantee cost-containment for pharmaceutical expenditures?
title Are biosimilars the next tool to guarantee cost-containment for pharmaceutical expenditures?
title_full Are biosimilars the next tool to guarantee cost-containment for pharmaceutical expenditures?
title_fullStr Are biosimilars the next tool to guarantee cost-containment for pharmaceutical expenditures?
title_full_unstemmed Are biosimilars the next tool to guarantee cost-containment for pharmaceutical expenditures?
title_short Are biosimilars the next tool to guarantee cost-containment for pharmaceutical expenditures?
title_sort are biosimilars the next tool to guarantee cost-containment for pharmaceutical expenditures?
topic Editorial
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3950601/
https://www.ncbi.nlm.nih.gov/pubmed/24271016
http://dx.doi.org/10.1007/s10198-013-0538-4
work_keys_str_mv AT farfanportetmariaisabel arebiosimilarsthenexttooltoguaranteecostcontainmentforpharmaceuticalexpenditures
AT gerkenssophie arebiosimilarsthenexttooltoguaranteecostcontainmentforpharmaceuticalexpenditures
AT lepagenefkensisabelle arebiosimilarsthenexttooltoguaranteecostcontainmentforpharmaceuticalexpenditures
AT vinckirmgard arebiosimilarsthenexttooltoguaranteecostcontainmentforpharmaceuticalexpenditures
AT hulstaertfrank arebiosimilarsthenexttooltoguaranteecostcontainmentforpharmaceuticalexpenditures

Ejemplares similares